NCT05640193View on ClinicalTrials.gov

A Study of LN-144 in People With Metastatic Melanoma to the Brain

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 25, 2022

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Metastatic Melanoma
Interventions
BIOLOGICAL

Lifileucel (LN-144)

A portion of the patient's tumor is resected and serves as the starting material for manufacturing lifileucel. After preparative NMA-LD, patients are infused with their autologous TIL (lifileucel), followed by a short course of high-dose IL-2.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

Sponsors
All Listed Sponsors
collaborator

Iovance Biotherapeutics, Inc.

INDUSTRY

collaborator

Stanford University

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT05640193 - A Study of LN-144 in People With Metastatic Melanoma to the Brain | Biotech Hunter | Biotech Hunter